Cargando…
Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease
BACKGROUND AND AIMS: Liver fibrosis predicts adverse clinical outcomes, such as liver-related death (LRD) and hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD). We aimed to investigate the accuracy of semi-automated quantification of collagen proportionate are...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522738/ https://www.ncbi.nlm.nih.gov/pubmed/37358741 http://dx.doi.org/10.1007/s12072-023-10564-3 |
_version_ | 1785110418109235200 |
---|---|
author | Wang, Zhengyi Jeffrey, Gary P. Huang, Yi De Boer, Bastiaan Garas, George Wallace, Michael Bertot, Luis Adams, Leon A. |
author_facet | Wang, Zhengyi Jeffrey, Gary P. Huang, Yi De Boer, Bastiaan Garas, George Wallace, Michael Bertot, Luis Adams, Leon A. |
author_sort | Wang, Zhengyi |
collection | PubMed |
description | BACKGROUND AND AIMS: Liver fibrosis predicts adverse clinical outcomes, such as liver-related death (LRD) and hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD). We aimed to investigate the accuracy of semi-automated quantification of collagen proportionate area (CPA) as an objective new method for predicting clinical outcomes. METHOD: Liver biopsies from patients with NAFLD underwent computerized image morphometry of Sirius Red staining with CPA quantification performed by ImageScope. Clinical outcomes, including total mortality, LRD, and combined liver outcomes (liver decompensation, HCC, or LRD), were determined by medical records and population-based data-linkage. The accuracy of CPA for predicting outcomes was compared with non-invasive fibrosis tests (Hepascore, FIB-4, APRI). RESULTS: A total of 295 patients (mean age 50 years) were followed for a median (range) of 9 (0.2–25) years totalling 3253 person-years. Patients with CPA ≥ 10% had significantly higher risks for total death [hazard ratio (HR): 5.0 (1.9–13.2)], LRD [19.0 (2.0–182.0)], and combined liver outcomes [15.6 (3.1–78.6)]. CPA and pathologist fibrosis staging (FS) showed similar accuracy (AUROC) for the prediction of total death (0.68 vs. 0.70), LRD (0.72 vs. 0.77) and combined liver outcomes (0.75 vs. 0.78). Non-invasive serum markers Hepascore, APRI, and FIB-4 reached higher AUROC; however, they were not statistically significant compared to that of CPA except for Hepascore in predicting total mortality (0.86 vs. 0.68, p = 0.009). CONCLUSION: Liver fibrosis quantified by CPA analysis was significantly associated with clinical outcomes including total mortality, LRD, and HCC. CPA achieved similar accuracy in predicting outcomes compared to pathologist fibrosis staging and non-invasive serum markers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-023-10564-3. |
format | Online Article Text |
id | pubmed-10522738 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer India |
record_format | MEDLINE/PubMed |
spelling | pubmed-105227382023-09-28 Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease Wang, Zhengyi Jeffrey, Gary P. Huang, Yi De Boer, Bastiaan Garas, George Wallace, Michael Bertot, Luis Adams, Leon A. Hepatol Int Original Article BACKGROUND AND AIMS: Liver fibrosis predicts adverse clinical outcomes, such as liver-related death (LRD) and hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD). We aimed to investigate the accuracy of semi-automated quantification of collagen proportionate area (CPA) as an objective new method for predicting clinical outcomes. METHOD: Liver biopsies from patients with NAFLD underwent computerized image morphometry of Sirius Red staining with CPA quantification performed by ImageScope. Clinical outcomes, including total mortality, LRD, and combined liver outcomes (liver decompensation, HCC, or LRD), were determined by medical records and population-based data-linkage. The accuracy of CPA for predicting outcomes was compared with non-invasive fibrosis tests (Hepascore, FIB-4, APRI). RESULTS: A total of 295 patients (mean age 50 years) were followed for a median (range) of 9 (0.2–25) years totalling 3253 person-years. Patients with CPA ≥ 10% had significantly higher risks for total death [hazard ratio (HR): 5.0 (1.9–13.2)], LRD [19.0 (2.0–182.0)], and combined liver outcomes [15.6 (3.1–78.6)]. CPA and pathologist fibrosis staging (FS) showed similar accuracy (AUROC) for the prediction of total death (0.68 vs. 0.70), LRD (0.72 vs. 0.77) and combined liver outcomes (0.75 vs. 0.78). Non-invasive serum markers Hepascore, APRI, and FIB-4 reached higher AUROC; however, they were not statistically significant compared to that of CPA except for Hepascore in predicting total mortality (0.86 vs. 0.68, p = 0.009). CONCLUSION: Liver fibrosis quantified by CPA analysis was significantly associated with clinical outcomes including total mortality, LRD, and HCC. CPA achieved similar accuracy in predicting outcomes compared to pathologist fibrosis staging and non-invasive serum markers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-023-10564-3. Springer India 2023-06-26 /pmc/articles/PMC10522738/ /pubmed/37358741 http://dx.doi.org/10.1007/s12072-023-10564-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Wang, Zhengyi Jeffrey, Gary P. Huang, Yi De Boer, Bastiaan Garas, George Wallace, Michael Bertot, Luis Adams, Leon A. Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease |
title | Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease |
title_full | Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease |
title_fullStr | Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease |
title_full_unstemmed | Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease |
title_short | Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease |
title_sort | liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522738/ https://www.ncbi.nlm.nih.gov/pubmed/37358741 http://dx.doi.org/10.1007/s12072-023-10564-3 |
work_keys_str_mv | AT wangzhengyi liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease AT jeffreygaryp liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease AT huangyi liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease AT deboerbastiaan liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease AT garasgeorge liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease AT wallacemichael liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease AT bertotluis liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease AT adamsleona liverfibrosisquantifiedbyimagemorphometrypredictsclinicaloutcomesinpatientswithnonalcoholicfattyliverdisease |